Clinical trials: Disease Exacerbation
Chronic Obstructive Pulmonary Disease
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)
The objective of the REACT trial is to investigate the effect of roflumilast 500 μg tablets once daily versus placebo on exacerbation rate and pulmonary function in COPD patients who are concomitantly treated with a fixed…
- Trial name
- REACT (NCT01329029)
- Testing
- Roflumilast
- Where
- 180 sites in Australia, Austria and 19 more
- Volunteers
- 1,945 people
- Sponsor
- AstraZeneca
COPD, COPD Exacerbation
Chronic Obstructive Pulmonary Disease (COPD) Monitoring
The present feasibility study aims at assessing whether the EMG of respiratory muscles can serve as an objective marker of dyspnea in COPD patients.
- Trial name
- COPD (NCT04671888)
- Testing
- exercises
- Volunteers
- 30 people
- Sponsor
- Medtronic BRC
Pulmonary Disease, Chronic Obstructive
Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.
This is a randomised, double-blind, double-dummy, multinational, multicentre, parallel group trial comparing tiotropium (18 mcg) inhalation capsule via HandiHaler and salmeterol (50 mcg) via MDI in patients with COPD.
- Trial name
- NCT00563381
- Testing
- Tiotropium bromide, Salmeterol
- Where
- 752 sites in Austria, Belgium and 23 more
- Volunteers
- 7,376 people
- Sponsor
- Boehringer Ingelheim
COPD (Chronic Obstructive Pulmonary Disease)
COPD Exacerbation Follow Up
The goal of this study is to evaluate the impact of implementing an AI-enabled clinical workflow tool (Viz COPD) on respiratory specialist follow up and clinical outcomes after an acute exacerbation.
- Trial name
- NCT07118306
- Where
- 5 sites in United States
- Volunteers
- 485 people
- Sponsor
- Viz.ai, Inc.
COPD (Chronic Obstructive Pulmonary Disease), COPD Exacerbation
A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPD
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-3750) in patients with mild to moderate chronic obstructive pulmonary disease (COPD)
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), COPD Exacerbation, COPD Exacerbation Acute
- Trial name
- R-3750-01-LU (NCT07076290)
- Testing
- R-3750
- Volunteers
- 27 people
- Sponsor
- Rise Therapeutics LLC
Respiratory Tract Infections
Evaluation of the Treatment With Klacid SR in Patients With Acute Tracheitis, Tracheobronchitis and Bronchitis, Acute Exacerbation of Chronic Bronchitis and Mild Community-acquired Pneumonia in Common Clinical Practice in Ukraine
To describe the relief of symptoms, tolerability, and compliance of treatment with Klacid® sustained release (SR) at a dose of 1000 mg once daily in patients with acute tracheitis, acute tracheobronchitis, acute bronchitis, or in…
- Trial name
- KLARAINE (NCT01095978)
- Testing
- Clarithromycin (Klacid SR)
- Where
- 126 sites in Ukraine
- Volunteers
- 2,822 people
- Sponsor
- Abbott
Schizophrenia
An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia
This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of acute exacerbation of schizophrenia during a 4-week inpatient treatment period.
- Trial name
- NCT01175135
- Testing
- PF-02545920, Risperidone
- Where
- 46 sites in United States, Germany and 1 more
- Volunteers
- 259 people
- Sponsor
- Pfizer
COPD Exacerbation, COPD
Telemonitoring System for Early Diagnosis of COPD Exacerbations.
A tailored management of COPD patients would obviously allow to reduce costs for hospitalizations and improve quality of life. This management could benefit of the Information and Comunication Technology support, which can offer…
- Trial name
- NCT03739957
- Testing
- BPCO Media Kit
- Where
- 3 sites in Italy
- Volunteers
- 500 people
- Sponsor
- Laboratori di Informatica Applicata
Bronchitis, Chronic
Telithromycin: in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adult Outpatients With COPD
Non-inferiority efficacy of telithromycin versus azithromycin
- Trial name
- NCT00538148
- Testing
- Telithromycin
- Volunteers
- 668 people
- Sponsor
- Sanofi
Asthma, Vitamin D Deficiency
Rapid vs Maintenance Vitamin D Supplementation in Deficient Children With Asthma to Prevent Exacerbations.
The role of vitamin D in respiratory health remains uncertain. Whether vitamin D reduces clinically important exacerbations of childhood asthma remains uncertain.
- Trial name
- NCT01395589
- Testing
- Vitamin D
- Where
- Qatar
- Volunteers
- 597 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Schizophrenia
Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947)
Schizophrenia is a brain disease. The primary features of schizophrenia are characterized by Positive symptoms (symptoms that should not be there, inability to think clearly, to distinguish reality from fantasy i.e., hearing…
- Trial name
- NCT00151424
- Testing
- asenapine, Olanzapine
- Volunteers
- 277 people
- Sponsor
- Organon and Co
Chronic Obstructive Pulmonary Disease
Comparison Between Symbicort® and Prednisolone in COPD
To assess if Symbicort forte Turbuhaler (during two weeks) is as effective as an oral course of prednisolone + Oxis Turbuhaler (during two weeks) for the treatment of an acute exacerbation of Chronic Obstructive Pulmonary Disease…
- Trial name
- SPACE (NCT00259779)
- Testing
- budesonide/formoterol, Prednisolone
- Where
- 37 sites in Denmark, Finland and 3 more
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
COPD Exacerbation Acute
A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease, that causes obstructed airflow from the lungs that causes persistent obstructive airflow limitation.
- Trial name
- NCT05400369
- Testing
- Sitafloxacin, Moxifloxacin Hydrochloride
- Where
- 18 sites in China
- Volunteers
- 140 people
- Sponsor
- Daiichi Sankyo
Bronchiectasis
Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14…
- Trial name
- RESPIRE 1 (NCT01764841)
- Testing
- Ciprofloxacin DPI (BAYQ3939)
- Where
- 151 sites in United States, Argentina and 12 more
- Volunteers
- 416 people
- Sponsor
- Bayer
Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation
Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease
The purpose of this trial is to investigate if roflumilast can reduce the neutrophilic inflammation at acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- TREAT (NCT01473758)
- Testing
- Roflumilast
- Where
- 2 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- AstraZeneca
Asthma
The Predictors for Asthma Control by Stepwise Treatment During 6 Months in Korean Elderly
The Predictors for asthma control by stepwise treatment during 6 months in Korean elderly
- Trial name
- Prelude (NCT01370577)
- Where
- 5 sites in South Korea
- Volunteers
- 297 people
- Sponsor
- AstraZeneca
Bronchiectasis
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14…
- Trial name
- RESPIRE 2 (NCT02106832)
- Testing
- Ciprofloxacin (BAYQ3939) dry powder for inhalation
- Where
- 207 sites in United States, Argentina and 23 more
- Volunteers
- 521 people
- Sponsor
- Bayer
Pulmonary Disease, Chronic Obstructive
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1
A randomized, placebo-controlled, double-blind, parallel group, multi center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD)…
- Trial name
- NCT01663987
- Testing
- tiotropium bromide
- Where
- 50 sites in United States, Puerto Rico
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease, COPD
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
The purpose of this study is to determine whether roflumilast is effective in the treatment of exacerbations in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00076089
- Testing
- Roflumilast
- Where
- 40 sites in United States, Canada and 4 more
- Volunteers
- 1,100 people
- Sponsor
- AstraZeneca
Schizophrenia, Schizoaffective Disorder
A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
This study was conducted to examine the efficacy and tolerability of ziprasidone intramuscular (IM), and to assess the effect of switching from IM to oral ziprasidone for the treatment of acute exacerbation of schizophrenia and…
- Trial name
- NCT00650429
- Testing
- Ziprasidone
- Where
- 4 sites in Mexico
- Volunteers
- 28 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.